Article
Vernalis acquires US rights to Moxatag
Vernalis Therapeutics has acquired the U.S. rights to Pragma Pharmaceuticals' Moxatag (amoxicillin) extended-release tablets.
PRESS RELEASE
BERWYN, Pa. — Vernalis Therapeutics has added a new drug to its portfolio. The company announced Friday that its parent company had acquired the U.S. rights to Pragma Pharmaceuticals’ Moxatag (amoxicillin) extended-release tablets. The company will oversee the drug’s sale, marketing and distribution in the U.S.
“The addition of Moxatag … further underscores Vernalis Therapeutics' commitment to building a commercial presence in the U.S. market,” the company’s SVP commercial operations Tom Parker said. “We look forward to re-launching the product in early 2016, and believe it will be a natural complement to our recently launched 12-hour codeine-based prescription medication, Tuzistra XR, as both products offer patients and physicians an extended-release alternative to existing treatments.”
Moxatag is meant to treat tonsillitis or secondary pharyngitis in adults and children 12 years of age and older.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
